Strasser Florian
Oncological Palliative Medicine, Division of Oncology/Hematology, Department of Internal Medicine, Cantonal Hospital, St. Gallen, Switzerland.
Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):417-21. doi: 10.1097/MCO.0b013e3283025e27.
The classification of cachexia or wasting disease is currently being revised to improve clinical trial design and clinical care. Decreased muscle strength and fatigue are proposed as diagnostic criteria for cachexia or wasting disease including, but not limited to, cancer. This review discusses their expected value in cancer cachexia.
Fatigue is frequent and multifactorial in cancer patients with limited value to predict cachexia, however, most cachectic patients have fatigue. Its assessment requires multimodal subjective instruments, for outcome monitoring many other fatigue cofactors need to be controlled. Cachexia seems a dominant cause for decreased muscle strength. Most cachectic patients lose muscle strength, usually together with reduced muscle mass. High-individual variability of muscle strength limits its use to longitudinal monitoring. Physical activity monitoring, applying also body-worn sensors, offers additional monitoring tools.
To diagnose and monitor cachexia, muscle strength should be measured directly, whereas fatigue is seen as a global outcome.
目前正在修订恶病质或消耗性疾病的分类,以改进临床试验设计和临床护理。肌肉力量下降和疲劳被提议作为恶病质或消耗性疾病(包括但不限于癌症)的诊断标准。本综述讨论了它们在癌症恶病质中的预期价值。
疲劳在癌症患者中很常见且具有多因素性,对预测恶病质价值有限,然而,大多数恶病质患者都有疲劳症状。其评估需要多模式主观工具,对于结果监测,许多其他疲劳相关因素需要得到控制。恶病质似乎是肌肉力量下降的主要原因。大多数恶病质患者会出现肌肉力量丧失,通常还伴有肌肉量减少。肌肉力量的个体差异较大,限制了其在纵向监测中的应用。身体活动监测,包括使用可穿戴传感器,提供了额外的监测工具。
为了诊断和监测恶病质,应直接测量肌肉力量,而疲劳则被视为一个整体结果。